Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06834672CT.gov Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ibi354 (this asset) | Innovent Biologics (Suzhou) Co. Ltd. | P3 | B · 60 |
| Irinotecan | Xiaoxiang Chen | P3 | BB |
| Adriamycin | Innovent Biologics (Suzhou) Co. Ltd. | P3 | BB |
| Carboplatin | Fujian Cancer Hospital | P3 | BB |
| Olaparib | Xiaoxiang Chen | P2 | BB |
| Pembrolizumab | Sheba Medical Center | P2 | B |
| Dexasone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P2 | B |
| Temsirolimus | AGO Study Group | P2 | B |
| Trabectedin | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P2 | B |
+16 more in the Ovarian Disorder cohort
Other indications for ibi354
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P3 | B · 60 |
| HER2 Positive Breast Carcinoma | — | P3 | B · 56 |
| Breast Neoplasm | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ibi354 in Ovarian Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ibi354-ovarian-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →